Biotechnology

Wednesday Apr 06, 2022 - 11:37 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced its receipt of approval from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee (“EC”) SUD-EST III (“CPP Sud-Est III”) in France for the…

Wednesday Apr 06, 2022 - 11:17 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be represented at the Benzinga Psychedelics Capital Conference. The premier event is scheduled for April 19, 2022, and will be held in Miami Beach, Florida. Cybin CEO Doug Drysdale will present a fireside chat and will also be a member of a panel discussion. Drysdale’s chat is slated to start…

Tuesday Apr 05, 2022 - 11:59 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received key approval for a planned study. The approval came from Swissmedic, the Swiss agency for therapeutic products. CNSP can now move forward with its potentially pivotal study of its novel anthracycline, Berubicin, for the treatment of recurrent glioblastoma…

Friday Apr 01, 2022 - 3:00 pm

InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Technologies Stand Distinct

Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up to five days. Besides causing discomfort upon insertion, users report…

Thursday Mar 31, 2022 - 2:14 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Filing of Year-End 2021 Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the filing of its Annual Report on Form 20-F for the year ended Dec. 31, 2021, audited financial results for the fourth quarter and full year then ended and accompanying management discussion and analysis. According to the announcement, the filings…

Thursday Mar 31, 2022 - 10:08 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Enters Agreement to Significantly Advance Technologies ‘Closer to the Clinic’

Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals. “This agreement significantly advances our…

Tuesday Mar 29, 2022 - 2:30 pm

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, partnering to advance research and more. The company has partnered…

Monday Mar 28, 2022 - 12:20 pm

InvestorNewsBreaks – Pono Capital Corp (NASDAQ: PONOU), Benuvia Inc. Enter Definitive Business Combination Agreement

Pono (NASDAQ: PONOU), a publicly traded special purpose acquisition company, and Benuvia, a leading drug developer and manufacturer of active pharmaceutical ingredients focused on cannabinoids, with a growing portfolio of drug products and intellectual property, announced entry into a definitive business combination agreement that will result, subject to the satisfaction or waiver of certain closing conditions, in Benuvia becoming a public company. According to the…

Friday Mar 25, 2022 - 2:49 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) remains committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. “Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes,” reads a recent article. The piece discusses significant developments Lexaria has…

Friday Mar 25, 2022 - 2:20 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Committed to Execute More Programs to Grow Market Reach and Product Portfolio

InMed Pharmaceuticals (NASDAQ: INM) President and CEO Eric A. Adams recently hosted a conference call and webcast in which he emphasized the company’s successful product diversification and strategic acquisition achievements. He expressed his optimism at the company’s expansion into the health and wellness sector as an ingredient supplier and the integration of BayMedica’s operations and team into its ongoing activities. A recent article reads: “While…

Friday Mar 25, 2022 - 10:03 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved a key milestone. The milestones were identified in the Dec. 4, 2020, contribution agreement between Cybin and Adelia and include Year 1 Q4 (vi), Year 2 Q2 (ii), Year 2 Q2 (v) and Year 2, Q3 (iii). Others involved…

Thursday Mar 24, 2022 - 11:03 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has received conditional approval from the Institutional Review Board ("IRB") for its planned multisite phase 2b smoking cessation trial. According to the announcement, Johns Hopkins University will serve as the lead investigational site for the study. The company anticipates submitting its IND application in…

Wednesday Mar 23, 2022 - 12:20 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate at the 2022 Virtual Growth Conference. The event, presented by Maxim Group LLC and hosted by M-Vest, is slated to take place March 28-30, 2022. In addition to the…

Tuesday Mar 22, 2022 - 2:54 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Valuable AI-Powered Insights to Diabetes Market

Nemaura Medical (NASDAQ: NMRD), a medical technology company developing and commercializing non-invasive wearable diagnostic devices, is positioned to offer innovative solutions to a rapidly growing market. According to a recent report released by the International Diabetes Federation (“IDF”), diabetes is “spiraling out of control.” According to the report, 537 million adults live with diabetes, a number projected to rise to 643 million by 2030 and…

Friday Mar 18, 2022 - 2:03 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Commercialization Phase of Its Corporate Development, Recognizes First-Ever Revenues

Nemaura Medical (NASDAQ: NMRD) recently announced its Q3 FY 2022 results for the three months ended Dec. 31, 2021. The company reported revenues of $183,628 due to the initial shipments made over the past quarter of sugarBEAT(R) CGM devices to MySugarWatch, the company’s U.K. licensee. The order marked the inaugural revenues in Nemaura Medical’s history, with the company rapidly moving toward monetizing its recent product…

Thursday Mar 17, 2022 - 3:06 pm

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Playing Pivotal Role in Renaissance of Psychedelics

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is among organizations, working alongside researchers at the center of the veritable renaissance of psychedelics. “Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first- and second-generation novel compounds for the treatment of mental…

Thursday Mar 17, 2022 - 2:45 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in…

Thursday Mar 17, 2022 - 10:14 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Makes Changes in Management

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 2022; Colwill will serve as an advisor to the company through June 30, 2022, to ensure a smooth transition. The company has appointed Brenda Edwards as interim CFO…

Wednesday Mar 16, 2022 - 2:26 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues…

Tuesday Mar 15, 2022 - 10:05 am

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Medical Device Registration in New Zealand for Proprietary IoT System

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a medical device certification in New Zealand for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). This comes in coordination with Medical Kiwi Ltd. as local sponsor for the New Zealand certification. Medical Kiwi…

Friday Mar 11, 2022 - 3:11 pm

InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Revolutionary sugarBEAT(R) CGM Device Met with Early Success

Nemaura Medical (NASDAQ: NMRD), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices also simultaneously promote routine glucose testing in a bid to control blood glucose levels more effectively. Nemaura offers two flagship constant glucose monitoring (“CGM”) products: the sugarBEAT(R), a non-invasive wearable…

Friday Mar 11, 2022 - 1:15 pm

InvestorNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Announces Collaboration Agreement with RCFFN, University of Manitoba

AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York,…

Thursday Mar 10, 2022 - 11:29 am

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health Canada had included the dealer’s license, under which the company…

Wednesday Mar 09, 2022 - 11:31 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin, and addresses recent share price activity. “The divergence that exists between our operational strength and share price is top of…

Tuesday Mar 08, 2022 - 10:41 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at 34th Annual Roth Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that its president and CEO Eric A. Adams will be presenting at the 34th Annual Roth Conference being held March 13-15, 2022. Adams will host a fireside chat with Scoth Henry, managing director and head of pharmaceuticals research at Roth Capital Partners, on Tuesday, March 15. In…

Tuesday Mar 08, 2022 - 9:49 am

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Approval from Health Canada Recognizing RYAH Smart Medical Inhaler System as Medical Device

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received a Health Canada Medical Device License (“MDL”) for its proprietary Internet of Things (“IoT”) powered medical cannabis inhaler, proprietary cartridges and software application associated with the device (the “RYAH Smart Medical Inhaler System”). According to the update, Health Canada License number 107475 allows RYAH to market its Smart Medical Inhaler System…

Friday Mar 04, 2022 - 12:01 pm

InvestorNewsBreaks – Why AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Is ‘One to Watch’

AREV Life Sciences (CSE: AREV) (OTC: AREVF) is dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful industry collaborations. Its leadership team is focused on driving discovery programs for clinical complexities demonstrated by malnutrition, the inflammatory response system and viral infectious diseases. “AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board…

Thursday Mar 03, 2022 - 2:59 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market

InMed Pharmaceuticals (NASDAQ: INM) is uniquely positioned to leverage the growing worldwide awareness of the potential of cannabinoids and the rising demand for rare cannabinoids. The company has begun this year on a high, following the 2021 acquisition of BayMedica and the launch of cannabicitran (“CBT”) sales. “With the launch of business-to-business sales of CBT in the health and wellness sector, InMed has further expanded…

Thursday Mar 03, 2022 - 11:43 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the year ended Dec. 31, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.…

Thursday Mar 03, 2022 - 9:58 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that it will be attending three investor conferences in March. The upcoming events include the 34th Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference and Maxim Group’s Virtual Growth Conference. Members of Mydecine’s management team will be available for one-on-one…

Tuesday Mar 01, 2022 - 10:31 am

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer MYCO-001, in combination with therapy, to humans as part of…

Monday Feb 28, 2022 - 1:19 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Recognized as Innovator of the Year, Awarded Top Honors for Innovation in MedTech, Life Sciences

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its receipt of the top award as Innovator of the Year at the LeicestershireLive Innovation Awards 2022 held on Feb. 24, 2022. In addition, the company was awarded top honors for Innovation in MedTech and Life Sciences. “We are gratified…

Friday Feb 25, 2022 - 12:00 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement for Sale of Cobourg Facility for CAD$16.5M

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a life sciences holding company dedicated to building a portfolio of assets and biotech solutions. The company has announced its entry into a firm agreement in connection with the sale of its former Cobourg, Ontario-based cannabis processing facility and the 64.43-acre property on which the facility is located (the “transaction”). In consideration of the purchase of…

Wednesday Feb 23, 2022 - 1:58 pm

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Producing What Was Thought to Be Implausible

Nemaura Medical (NASDAQ: NMRD) has long focused on its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood markers at the surface of the skin. Its revolutionary sugarBEAT(R) constant glucose monitoring (“CGM”) device provides users with non-invasive glucose monitoring. Recently, the company released the MiBoKo application, an offering that uses a non-invasive…

Wednesday Feb 23, 2022 - 9:37 am

InvestorNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Achieves New Milestone, Opens Additional Revenue Stream

AREV Life Sciences (CSE: AREV) (OTC: AREVF) today announced completion of its fungi inoculation lab, colonizing and fruiting rooms. According to the update, the fruiting room has been populated with colonized blocks of Lion's Mane (Hericium erinaceus) containing bioactive substances with beneficial effects on the body, especially the brain, heart and gut. “This is another milestone achieved by the team. The fresh product and extract…

Tuesday Feb 22, 2022 - 1:19 pm

InvestorNewsBreaks – Genesis Unicorn Capital Corp. (NASDAQ: GENQU) Announces Closing of IPO, Full Exercise of Over-Allotment Option

Genesis Unicorn Capital (NASDAQ: GENQU) recently announced the closing of its initial public offering of 7,500,000 units, each at $10.00. Each unit consists of one share of Class A common stock and one warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. The underwriters fully exercised the over-allotment option for an additional 1,125,000 units…

Thursday Feb 17, 2022 - 11:31 am

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partners with University of Milan to Test, Evaluate New Line of Smart-Patch Wellness Products

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, will be collaborating with the University of Milan, Italy, on a new wellness line of topical patches. The partnership will be testing the permeation and effectiveness of the patches, which RYAH developed for its Smart Patch system. University…

Thursday Feb 17, 2022 - 10:22 am

InvestorNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Expands Corporate Efforts as It Advances Closer to Market with Milestone Products

AREV Life Sciences (CSE: AREV) (OTC: AREVF) today announced new corporate acquisitions and maturation of multiple product lines being matched with appointments and expanding corporate capacity in the company’s scientific advisory committee and IP council. The company has appointed Douglas Sorocco to its scientific advisory committee and IP council and has extended services with Strategic Health Resources LLC. These moves come as AREV’s expanding consumer…

Wednesday Feb 16, 2022 - 3:19 pm

InvestorNewsBreaks – Red White & Bloom Brands Inc.’s (CSE: RWB) (OTCQX: RWBYF) Warren Facility Providing Centralized Distribution, Production Capacity to Expand Sales

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has received full licensing for manufacturing both medical and adult-use cannabis products in Michigan, a state entering its third year under legislation allowing the legal sale of adult recreational-use cannabis. In addition, a recent article notes, “The company has closed on a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in Warren, Michigan, which…

Wednesday Feb 16, 2022 - 11:12 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions